CD133 has been recognized as a prominent biomarker for cancer stem cells (CSCs), which promote tumor relapse and metastasis. Here, we developed a clinically relevant, stable, and peptide-based positron emission tomography (PET) tracer, [Cu]CM-2, for mapping CD133 protein in several kinds of cancers. Through the incorporation of a 6-aminohexanoic acid (Ahx) into the N terminus of a CM peptide, we constructed a stable peptide tracer [Cu]CM-2, which exhibited specific binding to CD133-positive CSCs in multiple preclinical tumor models. Both PET imaging and ex vivo biodistribution verified the superb performance of [Cu]CM-2. Furthermore, the matched physical and biological half-life of [Cu]CM-2 makes it a state-of-the-art PET tracer for CD133. Therefore, [Cu]CM-2 PET may not only enable the longitudinal tracking of CD133 dynamics in the cancer stem cell niche but also provide a powerful and noninvasive imaging tool to track down CSCs in refractory cancers.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756568PMC
http://dx.doi.org/10.1021/acsomega.1c04711DOI Listing

Publication Analysis

Top Keywords

pet tracer
12
stable peptide-based
8
cancer stem
8
tracer [cu]cm-2
8
pet
5
[cu]cm-2
5
development stable
4
peptide-based pet
4
tracer
4
tracer detecting
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!